Microvascular network in renal carcinomas. Quantitative and tissue microarray immunohistochemical study

Polish Journal of Pathology

Volumn 59, Issue 2, 2008, Pages 107-115

  Okoń, Krzysztof ^a   Kawa, Rafał ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER STAGING; CLEAR CELL CARCINOMA; ENDOTHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; ONCOCYTOMA; PAPILLARY CARCINOMA; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY; TUMOR VOLUME;

ADENOMA, OXYPHILIC; ANTIGENS, CD34; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; GLUCOSE TRANSPORTER TYPE 1; HUMANS; KI-67 ANTIGEN; KIDNEY NEOPLASMS; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 47849089889     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Baldewijns MM, Thijssen VL, Van den Eynden GG, Van Laere SJ et al: High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br J Cancer 2007, 96, 1888-1895.
2. Banks RE, Craven RA, Harnden P, Madaan S et al: Key clinical issues in renal cancer: a challenge for proteomics. World J Urol 2007, 25, 537-556.
3. Burri PH, Hlushchuk R, Djonov V: Intussusceptive angiogenesis: its emergence, its characteristics, and its significanc. Dev Dyn 2004, 231, 474-488.
4. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407, 249-257.
5. Choueiri TK, Plantade A, Elson P, Negrier S et al: Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008, 26, 127-131.
6. Crivellato E, Nico B, Vaccu A, Djonov V et al: Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo. Leukemia 2004, 18, 331-336.
7. Delahunt B, Bethwaite PB, Thornton A: Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br J Urol 1997, 80, 401-404.
8. Döme B, Hendrix MJC, Paku S, Tóvári J et al: Alternative vascularization mechanisms in cancer: Pathology and therapeutic implicati. Am J Pathol 2007, 170, 1-15.
9. Eble JN, Sauter G, Epstein JI: Tumours of the kidney. In: Eble JN, Sauter G, Epstein JI Eds: WHO Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs (World Health Organization Classification of Tumours) 2004, 9-88.
10. Escudier B, Pluzanska A, Koralewski P, Ravaud A et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370, 2103-2111.
11. Ferrara N: Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000, 55, 15-35, discussion 35-36.
12. Fujimolo A, Onodera H, Mori A, Isobe N et al: Vascular endothelial growth factor reduces mural cell coverage of endothelial cells. Int J Exp Pathol 2004, 85, 355-364.
13. Gallou C, Joly D, Mejean A, Staroz F et al: Mutations of the VHL gene in sporadic renal cell carcinoma: definition of a risk factor for VHL patients to develop an RCC. Hum Mutat 1999, 13, 464-475.
14. Garcia JA, Rini BI: Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007, 57, 112-125.
15. Gelb AB: Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997, 80, 981-986.
16. Gelb AB, Sudilovsky D, Wu CD, Weiss LM et al: Appraisal of intratumoral microvessel density, MIB-1 score, DNA content, and p53 protein expression as prognostic indicators in patients with locally confined renal cell carcinoma. Cancer 1997, 80, 1768-1775.
17. Gunaratnam L, Morley M, Franovic A, de Paulsen N et al: Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem 2003, 278, 44966-44974.
18. Haitel A, Susani M Wick N, Mazal PR et al: c-kit overex-pression in chromophobe renal cell carcinoma is not associated with c-kit mutation of exons 9 and 11. Am J Surg Pathol 2005, 29, 842.
19. Henke R, Erbersdobler A: Numerical chromosomal aberrations in papillary renal cortical tumors: relationship with histopathologic features. Virchows Arch 2002, 440, 604-609.
20. Herman JG, Latif F, Weng Y Lerman MI et al:. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 1994, 91, 9700-9704.
21. Hillen F, Griffioen AW: Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 2007, 26, 489-502.
22. Igarashi H, Esumi M Ishida H, Okada K: Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer 2002, 95, 47-53.
23. Kavantzas N, Paraskevakou H, Tseleni-Balafouta S, Aroni K et al: Association between microvessel density and histologic grade in renal cell carcinomas. Pathol Oncol Res 2007, 13, 145-148.
24. Kenck C, Wilhelm M, Bugert P, Staehler G et al: Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas. J Pathol 1996, 179, 157-161.
25. Khoo SK, Kahnoski K, Sugimura J, Petillo D et al: Inactivation of BHD in sporadic renal tumors. Cancer Res 2003, 63, 4583-4587.
26. Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22, 4991-5004.
27. Kirkali Z, Yorukoglu K, Ozkara E, Kazimogiu H et al: Proliferative activity, angiogenesis and nuclear morphometry in renal cell carcinoma. Int J Urol 2001 , 8, 697-703.
28. Kondo K, Klco J, Nakamura E, Lechpammer M et al: Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002, 1, 237-246.
29. Lee JS, Jung JJ, Kim J: Quantification of angiogenesis by a computerized image analysis system in renal cell carcinoma. Anal Quant Cytol Histol 2000, 22, 469-474.
30. Lidgren A, Bergh A, Grankvist K, Rasmuson T etal: Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha. BJU Int 2007, 101, 480-484.
31. Linehan WM, Vasselli J, Srinivasan R, Walther MM et al: Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 2004, 10, 6282S-6289S.
32. MacLennan GT, Bostwick DG: Microvessel density in renal cell carcinoma: lack of prognostic significance. Urology 1995, 46, 27-30.
33. Maxwell PH, Wiesener MS, Chang GW, Clifford SC et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399, 271-275.
34. Mertz KD, Demichelis F, Kim R, Schraml P et al: Automated immunofluorescence analysis defines microvessel area as a prognostic parameter in clear cell renal cell cancer. Hum Pathol 2007, 38, 1454-1462.
35. Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM et al: Sunitinib efficacy against advanced renal cell carcinoma. J Urol 2007, 178, 1883-1887.
36. Paradis V, Lagha NB, Zeimoura L, Blanchet P et al: Expression of vascular endothelial growth factor in renal cell carcinomas. Virchows Arch 2000, 436, 351-356.
37. Petit A, Castillo M, Mellado B, Mallofre C: c-kit overexpression in chromophobe renal cell carcinoma is not associated with c-kit mutation of exons 9 and 11. Am J Surg Pathol 2005, 29, 1544-1545.
38. Petit A, Castillo M, Santos M, Mellado B et al: KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. Am J Surg Pathol 2004, 28, 676-678.
39. Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005, 23, 1028-1043.
40. Rudzki Z, Kawa R, Okoń K Szczygiel E et al: Objective, planimetry-based assessment of megakaryocyte histological pictures in Philadelphia-chromosome-negative chronic myeloproliferative disorders: a perspective for a valuable adjunct diagnostic tool. Virchows Arch 2006, 448, 59-67.
41. Sabo E, Boltenko A, Sova Y, Stein A et al: Microscopic analysis and significance of vascular architectural complexity in renal cell carcinoma. Clin Cancer Res 2001, 7, 533-537.
42. Schmidt LS, Nickerson ML, Angeloni D, Glenn GM et al:. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene. J Urol 2004, 172, 1256-1261.
43. Schraml P. Struckmann K, Hatz F, Sonnet S et al: VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol 2002, 196, 186-193.
44. Song KH, Song J, Jeong GB, Kim JM et al:. Vascular endothelial growth factor - its relation to neovascularization and their significance as prognostic factors in renal cell carcinoma. Yonsei Med J 2001, 42, 539-546.
45. Sweeney P, EI-Naggar AK, Lin S, Pisters LL: Biological significance of c-met over expression in papillary renal cell carcinoma. J Urol 2002, 168, 51-55.
46. Takahashi A, Sasaki H, Kim SJ, Tobisu K et al: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994, 54, 4233-4237.
47. Whitney VKM: Algorithm 422 minimal spanning tree. Commun Assoc Comput Mach 1972, 15, 273-274.
48. Yagasaki H, Kawala N, Takimoto Y, Nemoto N: Histopathological analysis of angiogenic factors in renal cell carcinoma. Int J Urol 2003, 10, 220-227.
49. Yamazaki K, Sakamoto M, Ohta T, Kanai Y et al: Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene 2003, 22, 847-852.
50. Yilmazer D, Han U, Onal B: A comparison of the vascular density of VEGF expression with microvascular density determined with CD34 and CD31 staining and conventional prognostic markers in renal cell carcinoma. Int Urol Nephrol 2007, 39, 691-698.